148 related articles for article (PubMed ID: 10846587)
1. Persisting HIV-1 replication triggered by acute hepatitis A virus infection.
Ridolfo AL; Rusconi S; Antinori S; Balotta C; Galli M
Antivir Ther; 2000 Mar; 5(1):15-7. PubMed ID: 10846587
[TBL] [Abstract][Full Text] [Related]
2. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
[No Abstract] [Full Text] [Related]
3. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
[No Abstract] [Full Text] [Related]
4. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy for patients failing their current antiretroviral regimen.
Albrecht MA
AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
[No Abstract] [Full Text] [Related]
6. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
[TBL] [Abstract][Full Text] [Related]
7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
8. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease inhibitors.
Eron JJ
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S160-70. PubMed ID: 10860901
[TBL] [Abstract][Full Text] [Related]
10. Successful simplification of HAART in patients with acute primary HIV infection.
Sinicco A; Bonora S; Arnaudo I; Zeme DA; Audagnotto S; Raiteri R; Di Perri G
J Biol Regul Homeost Agents; 2002; 16(1):69-72. PubMed ID: 12003178
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral update: recent advances expand options for patients with HIV.
Santhanam H; Goins M
Adv Nurse Pract; 2004 Nov; 12(11):53-4, 56. PubMed ID: 15559568
[No Abstract] [Full Text] [Related]
12. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
Cassol E; Page T; Mosam A; Friedland G; Jack C; Lalloo U; Kopetka J; Patterson B; Esterhuizen T; Coovadia HM
J Infect Dis; 2005 Feb; 191(3):324-32. PubMed ID: 15633090
[TBL] [Abstract][Full Text] [Related]
14. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance within the protease inhibitor class.
Race E
Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
[No Abstract] [Full Text] [Related]
16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
18. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
19. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
Gerber JG
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
[TBL] [Abstract][Full Text] [Related]
20. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
